Although poor medication adherence complicates the treatment of schizophrenia at all illness stages, interventions to maximize adherence at illness outset may be particulariy fruitful. Patients'initial perceptions about antipsychotics may influence long-term adherence, and eariy phase patients with any psychotic disorder pose an enormous challenge in treatment acceptance and adherence. Groups from around the world (e.g. Coldham et al. 2002;Novak-Grubic and Tavcar 2002;Robinson et al. 2002;Mutsatsa et al. 2003;Perkins et al. 2006;Kamali et al 2006) have reported substantial rates of medication nonadherence by patients with first episode schizophrenia. The consequences of nonadherence are profound. Maintenance treatment studies (Kane et al. 1982;Crow et al. 1986;McCreadie et al. 1989;Hogarty et al. 1998;Robinson et al. 1999;Gitlin et al. 2001;Wunderrink et al. 2007) have consistently shown maintenance antipsychotic treatment lowers relapse risk for patients with early phase schizophrenia. Studies that have followed subjects long term document a pattern of repeated relapses during the eariy illness course. Robinson and colleagues (1999) found that by 5 years of follow-up, 82% of subjects had experienced one relapse;78% of subjects who had recovered from their first relapse had a second relapse and 86% of subjects who recovered from their second relapse had a third relapse episode. Relapse risk was five times higher for patients who discontinued medication compared to those who continued medication. Although repeated relapses are detrimental to patients at all illness stages, they may have particular negative effects for eariy phase patients. Adolescence and eariy adulthood are a time when important developmental events such as finishing education, starting employment and establishing long-term relationships outside the family of origin are usually accomplished. Repeated relapses during this crucial period may disrupt successful completion of these tasks. Correlates of nonadherence in multi-episode patients include: more severe psychopathology, lack of insight, comorbid substance abuse, presence of medication side effects, an absence of social supports from family or friends, and practical barriers such as inability to afford medications. Despite the numerous studies of medication adherence in schizophrenia, information specifically about first episode patients is relatively limited. A number of factors suggest the need for separate study of recent onset patients. Due to their younger age, treatment decisions more often involve both patients and their families than is the case with multiepisode patients. Further, recent onset patients and their families lack experience with antipsychotics and with the chronic and relapsing course of schizophrenia. Their assessment of the benefits versus liabilities of antipsychotics may differ from those of multiepisode patients who have experienced the adverse consequences associated with repeated relapses.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-N)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
Kishimoto, T; Chawla, J M; Hagi, K et al. (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46:1459-72
Galling, Britta; Roldán, Alexandra; Nielsen, René E et al. (2016) Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry 73:247-59
Kane, John M; Robinson, Delbert G; Schooler, Nina R et al. (2016) Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry 173:362-72
Sarpal, Deepak K; Lencz, Todd; Malhotra, Anil K (2016) In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia. Am J Psychiatry 173:732-3
Sarpal, Deepak K; Argyelan, Miklos; Robinson, Delbert G et al. (2016) Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. Am J Psychiatry 173:69-77
Robinson, Delbert G; Gallego, Juan A; John, Majnu et al. (2015) A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull 41:1227-36
Galling, Britta; Correll, Christoph U (2015) Do antipsychotics increase diabetes risk in children and adolescents? Expert Opin Drug Saf 14:219-41
Zhang, Jian-Ping; Robinson, Delbert G; Gallego, Juan A et al. (2015) Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull 41:1248-55
Gerstenberg, Miriam; Hauser, Marta; Al-Jadiri, Aseel et al. (2015) Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. J Clin Psychiatry 76:e1449-58
Jensen, Karsten Gjessing; Juul, Klaus; Fink-Jensen, Anders et al. (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 54:25-36

Showing the most recent 10 out of 69 publications